- $582.74m
- $324.23m
- $283.47m
- 94
- 63
- 93
- 97
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.51 | ||
| Price to Tang. Book | 0.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.06 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -7.32% | ||
| Return on Equity | -3.76% | ||
| Operating Margin | -29.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 421.71 | 992.58 | 618.97 | 289.21 | 283.47 | 310.44 | 341.17 | 54.19% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +81.1 | -71.27 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Directors
- Ming Hsieh CHM (65)
- Paul Kim CFO (53)
- Jian Xie COO (55)
- Han Lin Gao CSO (54)
- John Bolger IND (74)
- Linda Marsh IND (71)
- Yun Yen IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 13th, 2016
- Public Since
- September 28th, 2016
- No. of Shareholders
- 11
- No. of Employees
- 1,313
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 30,865,730
- Address
- 4399 SANTA ANITA AVE, EL MONTE, 91731
- Web
- https://www.fulgentgenetics.com/
- Phone
- +1 6263500537
- Contact
- Melanie Solomon
- Auditors
- Deloitte & Touche LLP
Upcoming Events for FLGT
Q1 2025 Fulgent Genetics Inc Earnings Release
Fulgent Genetics Inc Annual Shareholders Meeting
Fulgent Genetics Inc Annual Shareholders Meeting
Q2 2025 Fulgent Genetics Inc Earnings Release
Similar to FLGT
Airsculpt Technologies
NASDAQ Global Market
Biodesix
NASDAQ Global Market
Burning Rock Biotech
NASDAQ Global Market
Exagen
NASDAQ Global Market
InterCure
NASDAQ Global Market
FAQ
What is the Fulgent Genetics share price?
As of Today at 20:43 UTC, shares in Fulgent Genetics are trading at $18.88. This share price information is delayed by 15 minutes.
How has the Fulgent Genetics share price performed this year?
Shares in Fulgent Genetics last closed at $18.88 and the price had moved by -5.74% over the past 365 days. In terms of relative price strength the Fulgent Genetics share price has underperformed the S&P500 Index by -13% over the past year.
What are the analyst and broker recommendations for Fulgent Genetics?
The overall consensus recommendation for Fulgent Genetics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Fulgent Genetics dividend yield?
Fulgent Genetics does not currently pay a dividend.
Does Fulgent Genetics pay a dividend?
Fulgent Genetics does not currently pay a dividend.
When does Fulgent Genetics next pay dividends?
Fulgent Genetics does not currently pay a dividend.
How do I buy Fulgent Genetics shares?
To buy shares in Fulgent Genetics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Fulgent Genetics?
As of the previous close price of $18.88, shares in Fulgent Genetics had a market capitalisation of $582.74m.
Where are Fulgent Genetics shares listed?
Here are the trading details for Fulgent Genetics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: FLGT
What kind of share is Fulgent Genetics?
Based on an overall assessment of its quality, value and momentum Fulgent Genetics is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Fulgent Genetics share price forecast for 2025?
The analyst consensus target price for shares in Fulgent Genetics is $20.00. That is 5.93% above the last closing price of $18.88.
Analysts covering Fulgent Genetics currently have a consensus Earnings Per Share (EPS) forecast of -$0.66 for the next financial year.
Find out moreWhat is the trend in the Fulgent Genetics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fulgent Genetics. Over the past six months, its share price has outperformed the S&P500 Index by +2.47%.
As of the last closing price of $18.88, shares in Fulgent Genetics were trading -3.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Fulgent Genetics PE Ratio?
The Fulgent Genetics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $18.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Fulgent Genetics?
Fulgent Genetics' management team is headed by:
- Ming Hsieh - CHM
- Paul Kim - CFO
- Jian Xie - COO
- Han Lin Gao - CSO
- John Bolger - IND
- Linda Marsh - IND
- Yun Yen - IND